A multi-center phase I/II study of melphalan, prednisone, thalidomide and defibrotide in avanced multiple myeloma patients.

被引：3
|
作者：
Palumbo, Antonio
Rus, Cecilia
Rossi, Davide
Pregno, Patrizia
Ambrosini, Maria Teresa
Avonto, Ilaria
Gay, Francesca
Cavallo, Federica
Iacobelli, Massimo
Gaidano, Gianluca
Mitsiades, Constantine
Richardson, Paul G.
Anderson, Kenneth C.
Boccadoro, Mario
机构：
[1] Univ Turin, Azienda Osped San Giovanni Battista, Div Ematol, Turin, Italy
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3560.3560
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3560
引用
收藏
页码：1016A / 1017A
页数：2
相关论文
共 50 条
  • [41] Prognostic factors in advanced multiple myeloma patients treated with the association of bortezomib, melphalan, prednisone and thalidomide (VMPT)
    Palumbo, A.
    Gay, F.
    Ambrosini, M. T.
    Benevolo, G.
    Pregno, F.
    Pescosta, N.
    Callea, V
    Cangialosi, C.
    Caravita, T.
    Morabito, F.
    Musto, P.
    Larocca, A.
    Caltagirone, S.
    Avonto, I
    Cavallo, F.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 140 - 140
  • [42] Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    Palumbo, Antonio
    Bringhen, Sara
    Liberati, Anna M.
    Caravita, Tommaso
    Falcone, Antonietta
    Callea, Vincenzo
    Montanaro, Marco
    Ria, Roberto
    Capaldi, Antonio
    Zambello, Renato
    Benevolo, Giulia
    Derudas, Daniele
    Dore, Fausto
    Cavallo, Federica
    Gay, Francesca
    Falco, Patrizia
    Ciccone, Giovannino
    Musto, Pellegrino
    Cavo, Michele
    Boccadoro, Mario
    BLOOD, 2008, 112 (08) : 3107 - 3114
  • [43] ORAL MELPHALAN, PREDNISONE AND THALIDOMIDE IN ELDERLY MULTIPLE MYELOMA PATIENTS: UPDATED RESULTS OF A RANDOMIZED CONTROLLED TRIAL
    Palumbo, A.
    Bringhen, S.
    Liberati, A. M.
    Caravita, T.
    Falcone, A.
    Callea, V.
    Cangialosi, C.
    Grasso, M.
    Galli, M.
    Rossini, F.
    Catalano, L.
    De Stefano, V.
    Morandi, S.
    Petrucci, M. T.
    Falco, P.
    Larocca, A.
    Magarotto, V.
    Ciccone, G.
    Cavo, M.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 364 - 365
  • [44] A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
    Sacchi, Stefano
    Marcheselli, Raffaella
    Lazzaro, Antonio
    Morabito, Fortunato
    Fragasso, Alberto
    Di Renzo, Nicola
    Balleari, Enrico
    Neri, Santo
    Quarta, Giovanni
    Ferrara, Raimondo
    Vigliotti, Maria Luigia
    Polimeno, Giuseppe
    Musto, Pellegrino
    Consoli, Ugo
    Zoboli, Alessandra
    Buda, Gabriele
    Pastorini, Alessandro
    Masini, Luciano
    LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1942 - 1948
  • [45] Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat In Patients with Relapsed/Refractory MM: a Phase I-II Study.
    Offidani, Massimo
    Cavallo, Federica
    Polloni, Claudia
    Liberati, Anna Marina
    Ballanti, Stelvio
    Pulini, Stefano
    Catarini, Massimo
    Alesiani, Francesco
    Corvatta, Laura
    Gentili, Silvia
    Boccadoro, Mario
    Leoni, Pietro
    Palumbo, Antonio
    BLOOD, 2010, 116 (21) : 1243 - 1244
  • [46] Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients
    Boccadoro, M.
    Bringhen, S.
    Gaidano, G.
    Ria, R.
    Offidani, M.
    Patriarca, F.
    Nozzoli, C.
    Musto, P.
    Petrucci, M.
    Palumbo, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] INTERFERON-ALPHA-2 MELPHALAN/PREDNISONE IN PREVIOUSLY UNTREATED PATIENTS WITH MULTIPLE-MYELOMA - A PHASE I-II TRIAL
    COOPER, MR
    FEFER, A
    THOMPSON, J
    CASE, DC
    KEMPF, R
    SACHER, R
    NEEFE, J
    BICKERS, J
    SCARFFE, JH
    SPIEGEL, R
    BONNEM, E
    CANCER TREATMENT REPORTS, 1986, 70 (04): : 473 - 476
  • [48] Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
    Beksac, Meral
    Haznedar, Rauf
    Firatli-Tuglular, Tulin
    Ozdogu, Hakan
    Aydogdu, Ismet
    Konuk, Nahide
    Sucak, Gulsan
    Kaygusuz, Isik
    Karakus, Sema
    Kaya, Emin
    Ali, Ridvan
    Gulbas, Zafer
    Ozet, Gulsum
    Goker, Hakan
    Undar, Levent
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (01) : 16 - 22
  • [49] Phase I/II study of decitabine in patients with myelodysplastic syndrome: A multi-center study in Japan
    Oki, Yasuhiro
    Kondo, Yutaka
    Yamamoto, Kazuhito
    Ogura, Michinori
    Kasai, Masanobu
    Kobayashi, Yukio
    Watanabe, Takashi
    Uike, Naokuni
    Ohyashiki, Kazuma
    Okamoto, Shin-ichiro
    Ohnishi, Kazunori
    Tomita, Akihiro
    Miyazaki, Yasushi
    Tohyama, Kaoru
    Mukai, Harumi Y.
    Hotta, Tomomitsu
    Tomonaga, Masao
    CANCER SCIENCE, 2012, 103 (10) : 1839 - 1847
  • [50] Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial
    White, Darrell J.
    Bahlis, Nizar J.
    Marcellus, Deb C.
    Belch, Andrew
    Stewart, A. Keith
    Chen, Christine
    Kovacs, Michael J.
    Macdonald, David A.
    Reece, Donna E.
    Reiman, Tony
    Harnett, Erica
    Meyer, Ralph M.
    Chapman, Judy-Anne W.
    Couban, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (01): : 19 - 24
12345